In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …

Structured abstract for full paper Background After recovery from COVID-19, most patients
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …

BACKGROUND Neutralizing antibodies are considered a key correlate of protection by
current SARS-CoV-2 vaccines. The manner in which human infections respond to …

As more and more patients recover from coronavirus disease 2019 (COVID-19) in the
coming weeks, convalescent plasma will become increasingly accessible as a treatment …

Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective …

BACKGROUND Although convalescent plasma has been widely used to treat severe
coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support …

Background Convalescent plasma has been widely used to treat coronavirus disease 2019
(Covid-19) under the presumption that such plasma contains potentially therapeutic …

Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …

Abstract Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …